




Supplementary figure 2. RAS CUSUM curve of hospital A.




Supplementary figure 3. **RAS** CUSUM curve of hospital B.




Supplementary figure 4. RAS CUSUM curve of hospital C.



Supplementary figure 5. RAS CUSUM curve of hospital D.




Supplementary figure 6. RAS CUSUM curve of hospital E.



Black arrow marks the introduction of ROSE regularly.






a: period Jan 2015 - Dec 2018

b: period June 2015 - Aug 2017

Black arrow marks the introduction of ROSE regularly.


DYM: diagnostic yield of malignancy



Black arrow marks the introduction of ROSE regularly. DYM: diagnostic yield of malignancy

- Lower decision limit

- Upper decision limit



a: period Jan 2015 - Dec 2018

b: period Jan 2016 - Dec 2018

Black arrow marks the introduction of ROSE regularly

DYM: diagnostic yield of malignancy

Supplementary tables

Supplementary table 1. RAS, rate of atypia, DYM and SFM before, during and after a period of absence of a senior pathologist in hospital C.

Period	RAS	Rate of atypia	DYM	SFM
Before 12-05-2017 (n=53)	51 (96%)	2 (4%)	38 (72%)	81%
Between 12-05-2017 and 12-09-2017 (n=10)	10 (100%)	4 (40%)	2 (20%)	40%
After 12-09-2017 (n=27)	26 (96%)	3 (11%)	19 (70%)	83%

RAS: rate of adequate sample DYM: diagnostic yield of malignancy SFM: sensitivity for malignancy

Supplementary table 2. RAS, DYM en SFM per year, per hospital

Period	d 2015 - 2018									2017			2018							
	Number of				Number of			Number of					Number of			Number of				
Hospital	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM
Α	87	<u>75</u>	53	68%	23	<u>20</u>	12	55%	8	<u>8</u>	<u> 7</u>	<u>88%</u>	39	<u>33</u>	23	70%	17	14	11	69%
		<u>(86%)</u>	(61%)			<u>(87%)</u>	(52%)			(100%)	(88%)			<u>(85%)</u>	(59%)			(82%)	(65%)	
В	91	<u>82</u>	57	71%	24	<u>33</u>	12	52%	13	<u>11</u>	7	64%	18	14	11	73%	36	<u>34</u>	<u>27</u>	<u>87%</u>
		<u>(90%)</u>	(63%)			<u>(96%)</u>	(50%)			<u>(85%)</u>	(54%)			(78%)	(61%)			<u>(94%)</u>	<u>(75%)</u>	
С	90	<u>87</u>	59	79%	24	<u>23</u>	<u>18</u>	<u>90%</u>	27	<u>26</u>	18	72%	23	<u>23</u>	12	75%	16	<u>15</u>	11	79%
		<u>(97%)</u>	(66%)			<u>(96%)</u>	<u>(75%)</u>			<u>(96%)</u>	(67%)			(100%)	(52%)			<u>(94%)</u>	(69%)	
D	100	<u>99</u>	<u>75</u>	<u>87%</u>	18	<u>18</u>	<u>13</u>	<u>87%</u>	18	<u>18</u>	12	80%	34	<u>33</u>	<u>25</u>	83%	30	<u>30</u>	<u>25</u>	<u>96%</u>
		<u>(99%)</u>	<u>(75%)</u>			<u>(100%)</u>	<u>(72%)</u>			(100%)	(67%)			<u>(97%)</u>	<u>(74%)</u>			(100%)	<u>(83%)</u>	
Ε	63	<u>56</u>	41	73%	9	6	1	20%	12	<u>11</u>	<u>10</u>	83%	22	<u>19</u>	15	71%	20	<u>20</u>	<u>15</u>	83%
		<u>(89%)</u>	(65%)			(67%)	(11%)			<u>(92%)</u>	<u>(83%)</u>			<u>(86%)</u>	(68%)			(100%)	<u>(75%)</u>	
Total	431	<u> 399</u>	285	76%	98	<u>90</u>	56	66%	78	<u>74</u>	54	76%	136	<u>122</u>	86	75%	119	<u>113</u>	<u>89</u>	<u>85%</u>
cohort		<u>(93%)</u>	(66%)			<u>(92%)</u>	(57%)			<u>(95%)</u>	(69%)			<u>(90%)</u>	(63%)			<u>(95%)</u>	<u>(75%)</u>	

<u>Italics and underlined</u>: equal or above ASGE performance target.

RAS: rate of adequate sample DYM: diagnostic yield of malignancy SFM: sensitivity for malignancy

Supplementary table 3. Key performance indicators for both FNA and FNB.

		2015			2016			2017				2018								
Needle	Number of				Number of				Number of				Number of				Number of			
type	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM	procedures	RAS	DYM	SFM
FNA	282	93%	67%	75%	57	95%	58%	60%	50	96%	72%	80%	93	87%	62%	73%	82	95%	74%	86%
FNB	127	95%	69%	82%	26	92%	73%	95%	27	96%	67%	72%	39	95%	62%	77%	35	94%	77%	84%

RAS: rate of adequate sample DYM: diagnostic yield of malignancy SFM: sensitivity for malignancy FNA: fine needle aspiration FNB: fine needle biopsy